Dexcom CGM creates visibility that blood glucose monitoring cannot
Dexcom ONE+ and Dexcom G7 is an all-in-one wearable that measures glucose levels 24 hours a day using a sensor inserted just under the skin. It sends current glucose values along with arrows indicating the direction and speed of glucose changes to a smartphone† or optional receiver in real-time, without fingerpricks.*
This continuous data aids in proactively managing glucose levels, offering insights into the impact of factors like meals, exercise and insulin on glucose fluctuations.
* If your glucose alerts and readings from the device do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Visible highs and lows
The complete glucose picture in real-time
How it works
All-in-one sensor
Measures interstitial glucose levels for up to 10 days, with a 12-hour grace period.
One-push applicator
Inserts the sensor. Its clever design means the user only has to push a button to get started.
Dexcom ONE+ app
Dexcom ONE+ app displays readings in real-time on your smartphone.†
The optional Dexcom Follow app's share feature allows friends, loved ones or caretakers to view the patient's glucose data directly from their smart device and receive customisable high/low glucose alerts.‡
Optional receiver§
Displays readings in real-time. The 11.9 mm slim design makes it ideal for users without a compatible smartphone.
For people with type 1 and type 2 diabetes
Funded for people living with type 1 diabetes††
Zero fingerpricks*
Waterproof^
Over 90% of Dexcom customers find Dexcom easy to use||,2
* If your glucose alerts and readings from the device do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Smart devices sold separately†
Easy for you
Self-start CGM for your patients.
Dexcom Clarity integration for simple pattern analysis and actionable insights.
Your patients can share their glucose data with you directly from the Dexcom app.¶
Easy for your patients
All-in-one wearable with simple insertion and self-setup in app.
Adults 65+ report high usability with a set up time of 12.6 minutes.3
Offers high and low alerts with optional customisation, including our unique Delay First High option, allowing patients to delay their first high alert after a meal to reduce alert fatigue.
Superior accuracy#,4
Along with Dexcom G7, Dexcom ONE+ is our most accurate CGM system, giving patients the confidence to make informed treatment decisions.**,4
8.2% overall adult MARD (back of the arm).5
95.3% repeatable precision in adults.‡‡,5
† Smart devices sold separately
Better health outcomes4,6-8
Dexcom CGM is the most researched CGMwith over 250 registered clinical trials10 and is shown to benefit the lives of people managing their glucose levels through real world clinical outcomes.11
In a real world study, average HbA1c levels decreased by 2.4% (from 9.4% to 7.1%, P < 0.001) over 6 months.12
Proven to improve time in range (3.9 mmol/L - 10.0 mmol/L) in type 2 diabetes.6,8,13
Shown toimprove overall wellbeing and quality of life.13,14
Demonstrated to reduce total daily insulin dose and weight in type 2 diabetes.§§,13
^ The Dexcom ONE+ sensor is waterproof and may be submerged under 2.4 metres of water for up to 24 hours without failure when properly installed.
Dexcom CGMs are now funded
Pharmac is providing access to funded CGMs for all Kiwis living with type 1 diabetes.††
†† Dexcom is fully funded under special authority criteria - a prescription item payment may be charged.
Sign up below and access our free comprehensive learning hub which includes tailored training modules that award certificates upon completion and exclusive HCP resources.
Always read the label and follow the directions for use. Read the warnings available on dexcom.com/downloadsandguides before purchasing. Consult your healthcare professional to see which product is right for you. This product is a continuous glucose monitoring system indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated. The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people living with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective glucose management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities.
* If your glucose alerts and readings from the device do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions; † Smart device sold separately. Connected compatible smart device required to display readings on smartwatch. For a list of compatible smart devices, visit dexcom.com/compatibility; ‡ Separate Follow app and internet connection required. Do not make treatment decisions based upon Follow readings. Always confirm with your compatible smart device or receiver; § A receiver can be acquired as an optional display device; || Results obtained with Dexcom G7 study, which shares similar features and usability as ONE+; ¶ Internet connection required to send data to Dexcom Clarity; # As compared to Dexcom G6 system; ^ The Dexcom ONE+ sensor is waterproof and may be submerged under 2.4 metres of water for up to 24 hours without failure when properly installed; ** Compared to previous generations of Dexcom systems; †† Eligibility criteria applies. Please visit pharmac.govt.nz; ‡‡ Precision reflects the consistency of CGM measurements. It is evaluated using the %20/20 rule, ensuring CGM readings are within 1.1 mmol/L of the true value for levels below 3.9 mmol/L, and within 20% for levels above 3.9 mmol/L; §§ Secondary outcome,(p<0.05). Incretin and SGLT2 use was similar with CGM and BGM and likely contributed to weight loss outcomes.
References
1. Seagrove Diabetes Bluebook 2024; 2 Dexcom, Data on File, 2023; 3 Psavko S, et al. JMIR Hum Factors. 2022;9(4):e42057; 4 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7; 5 Garg SK, et al. Diabetes Technol Ther. 2022;24(6):373-80; 6 Beck RW, et al. JAMA. 2017;317(4):371-8; 7 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374; 8 Martens T, et al. JAMA. 2021;325(22):2262-2272; 9 Laffel LM, et al. JAMA. 2020;323(23):2388-2396; 10 clinicaltrials.gov; 11 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39; 12 Grace et al. Clin Diabetes 2024;42(4):540–546; 13 Lind N et al. Diabetes Care. 2024;47(5):1-9;14 Lind M, et al. JAMA. 2017;317(4):379-87.
